Melillo G, Cocco G
Eur J Respir Dis. 1986 Nov;69(5):316-20.
Ambroxol is a new compound which increases secretion of phosphatidylcholine by type II pneumocytes. The secretion of phosphatidylcholine could affect bronchial hyperreactivity in two ways: by increasing lysophosphatidylcholine turnover and/or by modifying the layer of bronchial secretion that covers airway receptors. To see whether ambroxol affects bronchial hyperreactivity, we carried out a double-blind cross-over study, evaluating the efficacy of this drug vs placebo in modifying methacholine PD20 in 11 asthmatic patients, 4 atopics and 7 non-atopics. 90 mg of ambroxol or placebo were randomly administered orally for one of two 14-day periods. Methacholine PD20 was evaluated before and after each treatment. A highly significant difference was demonstrated in the direct comparison between ambroxol and placebo as to their ability to modify mean metacholine PD20, which with ambroxol was more than double that with placebo. It was also seen that ambroxol induced a significant increase in baseline values of PD20, i.e. a significant decrease in bronchial hyperreactivity. Placebo did not do this.
氨溴索是一种新型化合物，可增加II型肺细胞的磷脂酰胆碱分泌。磷脂酰胆碱的分泌可通过两种方式影响支气管高反应性：增加溶血磷脂酰胆碱的周转率和/或改变覆盖气道受体的支气管分泌物层。为了观察氨溴索是否影响支气管高反应性，我们进行了一项双盲交叉研究，评估该药物与安慰剂对11名哮喘患者（4名特应性患者和7名非特应性患者）的乙酰甲胆碱PD20的改善效果。在两个14天周期中的一个周期内，随机口服90毫克氨溴索或安慰剂。在每次治疗前后评估乙酰甲胆碱PD20。在直接比较氨溴索和安慰剂改变平均乙酰甲胆碱PD20的能力时，发现了极显著差异，使用氨溴索时的数值是使用安慰剂时的两倍多。还发现氨溴索可使PD20的基线值显著增加，即支气管高反应性显著降低。安慰剂则没有这种效果。
